{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:31:01Z","timestamp":1792416661475,"version":"4.4.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100019782","name":"Columbian College of Arts and Sciences, George Washington University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>\n                    New HIV treatment modalities, including long-acting injectable antiretroviral therapy (LAI-ART), increase the range of options available to people with HIV (PWH). As new treatments become available, it is important to understand how PWH perceive these new options and the role of providers in informing patients about them. We explored the perspectives of gay, bisexual, and other men who have sex with men with HIV (MWH) on new HIV treatment modalities and provider communication about these modalities. Semi-structured interviews were conducted with a total of 18 MWH from the US (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 9) and Australia (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 9), who were recruited in partnership with two community organizations. Participants identified as gay, cisgender men aged 29\u201366 years (Median = 54). All reported taking oral ART and having an undetectable viral load. Two main themes were identified: (1) Long-acting injectables are not as simple as daily pills, and (2) Providers should inform patients about new HIV treatments. Most MWH perceived LAI-ART to be more complex compared with their current oral treatment regimen because of frequent clinic visits to receive injections, discomfort with needles, and concerns about missed doses and side effects. MWH believed providers should inform all patients about new treatments and were less likely to do so if they did not have a relationship with their patients, were not satisfied with patients\u2019 current treatment, or were limited on time. Standardizing patient education about new treatments and broadening information channels may enhance informed decision-making among PWH, including those most likely to benefit from new modalities.\n                  <\/jats:p>","DOI":"10.1177\/10872914261429683","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:55:49Z","timestamp":1773251749000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on Long-Acting Injectable Treatment and Related Provider Communication Among Men with HIV in Australia and the US Who Have Sex with Men"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2964-1584","authenticated-orcid":false,"given":"Kaosisochukwu C.","family":"Onochie","sequence":"first","affiliation":[{"name":"Department of Psychological and Brain Sciences, George Washington University, Washington, DC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holt","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kalwicz","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, George Washington University, Washington, DC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cama","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Brener","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Broady","sequence":"additional","affiliation":[{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Bavinton","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, George Washington University, Washington, DC, USA."},{"name":"Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia."},{"name":"Department of Prevention and Community Health, George Washington University, Washington, DC, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States 2018\u20132022. HIV Surveillance Supplemental Report Volume 29. U.S. Department of Health and Human Services: Atlanta GA; 2024. Available from: https:\/\/www.cdc.gov\/hiv-data\/nhss\/estimated-hiv-incidence-and-prevalence.html [Last accessed: September16 2025]."},{"key":"e_1_3_3_3_2","volume-title":"HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2024","author":"King J","year":"2024","unstructured":"King J, , Kwon J, , McManus H, et al. HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2024. The Kirby Institute, UNSW Sydney: Sydney, AU; 2024."},{"key":"e_1_3_3_4_2","volume-title":"StatPearls","author":"Kemnic TR","year":"2025","unstructured":"Kemnic TR, , Gulick PG. HIV Antiretroviral Therapy. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2025."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.8.1111"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.10.004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/20499361221149773"},{"key":"e_1_3_3_8_2","unstructured":"Therapeutic Goods Adminstration. CABENUVA Cabotegravir 400 Mg\/2 mL plus Rilpivirine 600 Mg\/2 mL Prolonged-Release Suspensions for Injection Vials (323784). 2021. Available from: https:\/\/www.tga.gov.au\/resources\/artg\/323784 [Last accessed: August9 2025]."},{"key":"e_1_3_3_9_2","unstructured":"U.S. Food and Drug Administration. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. 2021. Available from: https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection [Last accessed: August9 2025]."},{"key":"e_1_3_3_10_2","unstructured":"Australian Government Department of Health Disability and Ageing. Making Medicines More Affordable for More Australians. 2022. Available from: https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/making-medicines-more-affordable-for-more-australians [Last accessed: October18 2025]."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06214-9"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxaf016"},{"key":"e_1_3_3_13_2","unstructured":"Therapeutic Goods Administration. Sunlenca. Therapeutic Goods Administration (TGA). 2023. Available from: https:\/\/www.tga.gov.au\/resources\/auspmd\/sunlenca [Last accessed: January18 2026]."},{"key":"e_1_3_3_14_2","unstructured":"HIV.gov. FDA approves new HIV drug for adults with limited treatment options. 2023. Available from: https:\/\/www.hiv.gov\/blog\/fda-approves-new-hiv-drug-for-adults-with-limited-treatment-options [Last accessed: January18 2026]."},{"key":"e_1_3_3_15_2","unstructured":"The Pharmaceutical Benefits Scheme. LENACAPAVIR. Medicine Status Website. 2026. Available from: https:\/\/www.pbs.gov.au:443\/medicinestatus\/document\/1059.html [Last accessed: January18 2026]."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21050602"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1742869"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-023-00755-6"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054648"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234666"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2024.2383872"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0017"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2025.2534535"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2025.2534535"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1057\/s41292-018-0129-9"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2023.35.6.467"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2011.05.005"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12060159"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.5430\/jnep.v3n12p60"},{"issue":"1","key":"e_1_3_3_30_2","first-page":"34","article-title":"People living with HIV: Sources of information on antiretroviral treatment and preferences for involvement in treatment decision-making","volume":"12","author":"Kremer H","year":"2007","unstructured":"Kremer H, , Ironson G. People living with HIV: Sources of information on antiretroviral treatment and preferences for involvement in treatment decision-making. Eur J Med Res, 2007; 12(1):34\u201342.","journal-title":"Eur J Med Res"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2012.0418"},{"key":"e_1_3_3_32_2","volume-title":"Qualitative Inquiry and Research Design: Choosing Among Five Approaches","author":"Creswell JW","year":"2025","unstructured":"Creswell JW, , Poth CN. Qualitative Inquiry and Research Design: Choosing Among Five Approaches. 5th ed. Sage; 2025.","edition":"5"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117"},{"key":"e_1_3_3_34_2","unstructured":"Multicultural New South Wales. Guide: What Is CALD? 2022. Available from: https:\/\/multicultural.nsw.gov.au\/wp-content\/uploads\/2022\/11\/P3-GUIDE-What-is-CALD.pdf"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0076"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03817-z"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac293"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211000517"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0198"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-023-02142-1"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1599"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/00909880500278012"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2010.03.001"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1071\/AH080186"},{"key":"e_1_3_3_45_2","first-page":"452","article-title":"\u201cWe have a lot of information to share with each other\u201d: Understanding the value of peer-based health information exchange","volume":"15","author":"Veinot T","year":"2010","unstructured":"Veinot T. \u201cWe have a lot of information to share with each other\u201d: Understanding the value of peer-based health information exchange. Inf Res, 2010; 15:452.","journal-title":"Inf Res"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0250"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2025.0039"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003620"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10546-w"},{"key":"e_1_3_3_50_2","unstructured":"U.S. Food and Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention [Last accessed: October22 2025]."},{"key":"e_1_3_3_51_2","unstructured":"Gilead Sciences. Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection. n.d. Available from: https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection [Last accessed: September15 2025]."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261429683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261429683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261429683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:40:56Z","timestamp":1791621656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261429683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1177\/10872914261429683"],"URL":"https:\/\/doi.org\/10.1177\/10872914261429683","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}